Docetaxel grafted magnetic nanoparticles as dual-therapeutic agentia for targeting perfusion therapy of urethral carcinoma
Source abstract
Abstract
Although urethral carcinoma has a low incidence, it suffers from a poor curative rate for the low retention of medicine around urethra. In the present study, we developed a kind of magnetic targeting perfusion chemotherapy to detain the chemotherapeutic drugs. Docetaxel (TXT) grafted magnetic nanoparticles, of which size was around 40 nm, were obtained by the conjugation of TXT to amino-functionalized iron oxide (NH2@Fe3O4). They have shown great potential to be targeted to and stayed in desired position of urethra under the externally applied magnetism through in vitro mimic urethral study. Furthermore, they have validly inhibited the growth of direct-contacted human urethral squamous carcinoma cells in vitro (up to 56.34 %) by the combination effects of TXT and NH2@Fe3O4, however, less than 3 % of TXT released from the nanoparticles, which was very few to impair the adjacent normal cells and tissues. Therefore, this kind of novel agentia was expected to hold great potential in clinic urethral carcinoma therapy.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Urinary and Genital Oncology Studies · Urological Disorders and Treatments · Bladder and Urothelial Cancer Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (53)
Show source-provided references
1. Edge ASB (2003) Deglycosylation of glycoproteins with trifluoromethanesulphonic acid: elucidation of molecular structure and function. Biochem J 376:339–35010.1042/bj20030673 ↗
2. Chen Z, Yin J, Zhou Y, Zhang Y, Song L, Song M, Hu S, Gu N (2012) Dual enzyme-like activities of iron oxide nanoparticles and their implication for diminishing cytotoxicity. 6:4001–401210.1021/nn300291r ↗
3. Ciapetti G, Cenni E, Pratelli L, Pizzoferrato A (1993) In vitro evaluation of cell/biomaterial interaction by MTT assay. Biomaterials 14:359–36410.1016/0142-9612(93)90055-7 ↗
4. Coop H, Pettit L, Boon C, Ramachandra P (2013) Radical chemoradiotherapy for urethral squamous cell carcinoma: two case reports and a review of the literature. Case Rep Urol 19469010.1155/2013/194690 ↗
5. Crook J, Ma C, Grimard L (2009) Radiation therapy in the management of the primary penile tumor: an update. World J Urol 27:189–19610.1007/s00345-008-0309-5 ↗
6. Dalbagni G, Zhang Z, Lacombe L, Hen HW (1999) Male urethral carcinoma: analysis of treatment outcome. Urology 53:1126–113210.1016/S0090-4295(98)00659-1 ↗
7. DeSilva DM, Askwitt CC, Kaplan J (1996) Molecular mechanisms of iron uptake in eukaryotes. J Physiol Rev 76:31–4710.1152/physrev.1996.76.1.31 ↗
8. Devoy J, Melczer M, Antonie G, Remy A, Heilier JF (2013) Validation of a standardised method for determining beryllium in human urine at nanogram level. Anal Bioanal Chem 405:8327–833610.1007/s00216-013-7220-7 ↗
9. Elliott SP, Malaeb BS (2011) Long-term urinary adverse effects of pelvic radiaotherapy. World J Urol 29:35–4110.1007/s00345-010-0603-x ↗
10. El-Toni AM, Ibrahim MA, Labis JP, Khan A, Alhoshan M (2013) Optimization of synthesis parameters for mesoporous shell formation on magnetic nanocores and their application as nanocarriers for docetaxel cancer drug. Int J Mol Sci 14:11496–1150910.3390/ijms140611496 ↗
11. Gautier J, Allard-Vannier E, Munnier E, Soucé M, Chourpa I (2013) Recent advances in theranostic nanocarriers of doxorubicin based on iron oxide and gold nanoparticles. J Control Release 169:48–6110.1016/j.jconrel.2013.03.018 ↗
12. Ge G, Wu H, Xiong F, Zhang Y, Guo Z, Bian Z, Xu J, Gu C, Gu N, Chen X, Yang D (2013) The cytotoxicity evaluation of magnetic iron oxide nanoparticles on human aortic endothelial cells. Nanoscale Res Lett 8:21510.1186/1556-276X-8-215 ↗
13. Ghasemi M, Minier M, Tatoulian M, Arefi-Khonsari F (2007) Determination of amine and aldehyde surface densities: application to the study of aged plasma treated polyethylene films. Langmuir 23:11554–1156110.1021/la701126t ↗
14. Glynn-Tucker E (2005) Managing the side effects of chemotherapy and radiation therapy. Oncol Nurs Forum 32:690
15. Guo J, Yang W, Wang C (2013) Magnetic colloidal supraparticles: design, fabrication and biomedical applications. Adv Mater 25:5196–521410.1002/adma.201301896 ↗
16. He Q, Mason AB, Lyons BA, Tam BM, Nguyen V, MacGillivray RTA, Woodworth RC (2001) Spectral and metal-binding properties of three single-point tryptophan mutants of the human transferrin N-lobe. Biochem J 351:423–42910.1042/0264-6021:3540423 ↗
17. Huang X, Yi CX, Fan YJ, Zhang YX, Zhao LM, Liang ZQ, Pan J (2014) Magnetic Fe3O4 nanoparticles grafted with single-chain antibody (scFv) and docetaxel loaded β-cyclodextrin potential for ovarian cancer dual-targeting therapy. J Mat Sci Eng-Mater 42:325–33210.1016/j.msec.2014.05.041 ↗
18. Itoh J, Mistsuzuka K, Kimura S, Tanaka T, Yamamuro T, Yamashita S, Yamada S, Saito H, Kaiho Y, Arai Y (2013) Docetaxel, cisplatin and 5-fluorouracil chemotherapy with concurrent radiation for unresectable advanced urethral carcinoma. Int J Urol 21:422–42410.1111/iju.12333 ↗
19. Jain A, Thakur K, Kush P, Jain UK (2014) Docetaxel loaded chitosan nanoparticles: formulation, characterization and cytotoxicity studies. Int J Biol Macromol 69:546–55310.1016/j.ijbiomac.2014.06.029 ↗
20. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA-Cancer J Clin 59:225–24910.3322/caac.20006 ↗
21. Klein Y, Grinstein M, Cohn SM, Silverman JM, Klein, Kashtan H, Shamir MY (2012) Minute-to-minute urine flow rate variability: a new renal physiology variable. Anesh & Analg 115:843–84710.1213/ANE.0b013e3182625813 ↗
22. Kobayashi M, Nomura M, Yamada Y, Fujimoto N, Matsunoto T (2005) Bladder-sparing surgery and continent urinary diversion using the appendix (Mitrofanoff procedure) for urethral cancer. Int J Urol 12:581–58410.1111/j.1442-2042.2005.01107.x ↗
23. Li Y, Huang G, Zhang X, Li B, Chen Y, Lu T, Lu T, Xu F (2013a) Magnetic hydrogels and their potential biomedical applications. Adv Func Mater 23:660–67210.1002/adfm.201201708 ↗
24. Li Z, Shuai C, Li X, Li X, Xiang J, Li G (2013b) Mechanism of poly-l-lysine-modified iron oxide nanoparticles uptake into cells. J Biomed Mate Res A 101:2846–285010.1002/jbm.a.34580 ↗
25. Ling D, Hyeon T (2013) Chemical design of biocompatible iron oxide nanoparticles for medical applications. Small 9:1450–146610.1002/smll.201202111 ↗
26. Ling Y, Wei K, Lou Y, Gao X, Zhong S (2011) Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy. Biomaterials 32:7139–715010.1016/j.biomaterials.2011.05.089 ↗
27. Liu Y, Fang J, Kim YJ, Wong MK, Wang P (2014a) Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity. Mol Pharm 11:1651–166110.1021/mp5000373 ↗
28. Liu Y, Gao FP, Zhang D, Fan YS, Chen XG, Wang HJ (2014b) Molecular structural transformation regulated dynamic disordering of supramolecular vesicles as pH-responsive drug release systems. J Control Release 173:140–14710.1016/j.jconrel.2013.10.033 ↗
29. MacDonald V (2009) Chemotherapy: managing side effects and safe handling. Oncol Nurs Forum 32:690
30. MacGillivray RTA, Moore SA, Chen J, Anderson BF, Baker H, Lou Y, Bewley M, Smith CA, Murphy MEP, Wang Y, Mason AB, Woodeworth RC, Brayer GD, Baker EN (1998) Two high-resolution crystal structures of the recombinant N-Lobe of human Transferrin reveal a structural change implicated in iron release. Biochemistry 37:7919–792810.1021/bi980355j ↗
31. Manning J (2012) Case report: transitional cell carcinoma in situ within a urethral diverticulum. Int Urogynecol J 23:1801–180310.1007/s00192-012-1789-9 ↗
32. Mok H, Zhang M (2013) Superparamagnetic iron oxide nanoparticle-based delivery systems for biotherapeutics. Expert Opin Drug Del 10:73–8710.1517/17425247.2013.747507 ↗
33. Nakazawa S, Uemura M, Matsuzaki K, Yoshida T, Takao T, Tsujimura A, Nonomura N, Kiyo H (2013) Cardiorespiratory arrest due to acute pulmonary thromboembolism during chemotherapy for female urothelial carcinoma of urethra: a case report. Acta Urol Jap 59:287–292
34. Parks SK, Chiche J, Pouysségur J (2013) Disrupting proton dynamics and energy metabolism for cancer therapy. J Nat Rev Cancer 13:611–62310.1038/nrc3579 ↗
35. Patra HK, Khaliq NU, Romu T, Wiechec E, Borga M, Turner AP, Tiwari A (2014) MRI-visual order-disorder micellar nanostructures for smart cancer theranostics. Adv Healthc Mater 3:526–53510.1002/adhm.201300225 ↗
36. Pisanic TR II, Blackwell JD, Shubayev VI, Fiñones RR, Jin S (2007) Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. Biomaterials 28:2572–258110.1016/j.biomaterials.2007.01.043 ↗
37. Qiao R, Yang C, Gao M (2009) Superparamagnetic iron oxide nanoparticles: from preparations to in vivo MRI applications. J Mater Chem 19:6274–629310.1039/b902394a ↗
38. Reddy LH, Arias JL, Nicolas J, Couvreur P (2012) Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem Rev 112:5818–587810.1021/cr300068p ↗
39. Reis LO, Billis A, Ferreira FT, Ikari LY, Stellini RF, Ferreira U (2011a) Female urethral carcinoma: evidences to origin from Skene’s glands. Urol Oncol-Semi Ori 29:218–22310.1016/j.urolonc.2009.03.019 ↗
40. Reis LO, Ferreira F, Almeida M, Ferreira U (2011b) Urethral carcinoma: critical view on contemporary consecutive series. Med Oncol 28:1405–141010.1007/s12032-010-9609-x ↗
41. Shi S, Jia J, Guo X, Zhao Y, Liu B, Chen D, Guo Y, Zhang X (2012) Toxicity of iron oxide nanoparticles against osteoblasts. J Nanopart Res 14:109110.1007/s11051-012-1091-2 ↗
42. Singh R, Nalwa HS (2011) Medical applications of nanoparticles in biological imaging, cell labeling, antimicrobial agents, and anticancer nanodrugs. J Biomed Nanotechnol 7:489–50310.1166/jbn.2011.1324 ↗
43. Singh D, McMillan JM, Liu XM, Vishwasrao HM, Kabanov AV, Sokolsky-Papkov M, Gendelman HE (2014) Formulation design facilitates magnetic nanoparticle delivery to diseased cells and tissues. Nanomedicine 9:469–48510.2217/nnm.14.4 ↗
44. Sundaresan V, Menon JU, Rahimi M, Nguyen KT, Wadajkar AS (2014) Dual-responsive polymer-coated iron oxide nanoparticles for drug delivery and imaging applications. Int J Pharm 466:1–710.1016/j.ijpharm.2014.03.016 ↗
45. Trabulsi EJ, Censits JH (2010) Chemotherapy for penile and urethral carcinoma. Urol Clin North Am 37:467–47410.1016/j.ucl.2010.04.010 ↗
46. Van AV, Alfred WJ (2013) Current intravesical therapy for non-muscle invasive bladder cancer. Expert Opin Biol Ther 13:1371–138510.1517/14712598.2013.824421 ↗
47. Verbrugghe M, Verhaeghe S, Lauwaert K, Beeckman D, Hecke AV (2013) Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev 39:610–62110.1016/j.ctrv.2012.12.014 ↗
48. Wahajuddin SA (2012) Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int J Nanomed 7:3445–347110.2147/IJN.S30320 ↗
49. Wang YJ, Hussain SM, Krestin GP (2001) Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Euro Radiol 11:2319–233110.1007/s003300100908 ↗
50. Yang T, Jiang X, Yang C, Wang J, Lai H, Zheng W (2002) Establishment of human urethral squamous carcinoma (HUS-98) cells line. Chin J Urol 23:28
51. Yildirimer L, Thanh NTK, Loizidou M, Seifalian AM (2011) Toxicology and clinical potential of nanoparticles. Nanotoday 6:585–60710.1016/j.nantod.2011.10.001 ↗
52. Yu Z, Schmaltz RM, Bozeman TC, Paul R, Rishel MJ, Tsosie KS, Hecht SM (2013) Selective tumor cell targeting by the disaccharide moiety of bleomycin. J Am Chem Soc 135:2883–288610.1021/ja311090e ↗
53. Zhong M, Tang P (1995) Mechanisms of iron uptake by mammalian cells. BBA-Mol Cell Res 1269:205–214